7 research outputs found
Non-competitive androgen receptor inhibition in vitro and in vivo
Androgen receptor (AR) inhibitors are used to treat multiple human diseases, including hirsutism, benign prostatic hypertrophy, and prostate cancer, but all available anti-androgens target only ligand binding, either by reduction of available hormone or by competitive antagonism. New strategies are needed, and could have an important impact on therapy. One approach could be to target other cellular mechanisms required for receptor activation. In prior work, we used a cell-based assay of AR conformation change to identify non-ligand inhibitors of AR activity. Here, we characterize 2 compounds identified in this screen: pyrvinium pamoate, a Food and Drug Administration-approved drug, and harmol hydrochloride, a natural product. Each compound functions by a unique, non-competitive mechanism and synergizes with competitive antagonists to disrupt AR activity. Harmol blocks DNA occupancy by AR, whereas pyrvinium does not. Pyrvinium inhibits AR-dependent gene expression in the prostate gland in vivo, and induces prostate atrophy. These results highlight new therapeutic strategies to inhibit AR activity
Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents
We previously
reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM)
kinase, which is a target for novel radiosensitizing drugs. While
our initial lead, compound <b>4</b>, was relatively potent and
nontoxic, it exhibited poor stability to oxidative metabolism and
relatively poor selectivity against other kinases. The current study
focused on balancing potency and selectivity with metabolic stability
through structural modification to the metabolized site on the quinazoline
core. We performed extensive structure–activity and structure–property
relationship studies on this quinazoline ATM kinase inhibitor in order
to identify structural variants with enhanced selectivity and metabolic
stability. We show that, while the C-7-methoxy group is essential
for potency, replacing the C-6-methoxy group considerably improves
metabolic stability without affecting potency. Promising analogues <b>20</b>, <b>27g</b>, and <b>27n</b> were selected based
on in vitro pharmacology and evaluated in murine pharmacokinetic and
tolerability studies. Compound <b>27g</b> possessed significantly
improve pharmacokinetics relative to that of <b>4</b>. Compound <b>27g</b> was also significantly more selective against other kinases
than <b>4</b>. Therefore, <b>27g</b> is a good candidate
for further development as a potential radiosensitizer
Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents
We previously
reported a novel inhibitor of the ataxia-telangiectasia mutated (ATM)
kinase, which is a target for novel radiosensitizing drugs. While
our initial lead, compound <b>4</b>, was relatively potent and
nontoxic, it exhibited poor stability to oxidative metabolism and
relatively poor selectivity against other kinases. The current study
focused on balancing potency and selectivity with metabolic stability
through structural modification to the metabolized site on the quinazoline
core. We performed extensive structure–activity and structure–property
relationship studies on this quinazoline ATM kinase inhibitor in order
to identify structural variants with enhanced selectivity and metabolic
stability. We show that, while the C-7-methoxy group is essential
for potency, replacing the C-6-methoxy group considerably improves
metabolic stability without affecting potency. Promising analogues <b>20</b>, <b>27g</b>, and <b>27n</b> were selected based
on in vitro pharmacology and evaluated in murine pharmacokinetic and
tolerability studies. Compound <b>27g</b> possessed significantly
improve pharmacokinetics relative to that of <b>4</b>. Compound <b>27g</b> was also significantly more selective against other kinases
than <b>4</b>. Therefore, <b>27g</b> is a good candidate
for further development as a potential radiosensitizer
Single Diastereomer of a Macrolactam Core Binds Specifically to Myeloid Cell Leukemia 1 (MCL1)
A direct binding screen of 100 000
sp<sup>3</sup>-rich molecules
identified a single diastereomer of a macrolactam core that binds
specifically to myeloid cell leukemia 1 (MCL1). A comprehensive toolbox
of biophysical methods was applied to validate the original hit and
subsequent analogues and also established a binding mode competitive
with NOXA BH3 peptide. X-ray crystallography of ligand bound to MCL1
reveals a remarkable ligand/protein shape complementarity that diverges
from previously disclosed MCL1 inhibitor costructures
Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription
The transcription factor Max is a basic-helix-loop-helix leucine zipper (bHLHLZ) protein that forms homodimers or interacts with other bHLHLZ proteins, including Myc and Mxd proteins. Among this dynamic network of interactions, the Myc/Max heterodimer has crucial roles in regulating normal cellular processes, but its transcriptional activity is deregulated in a majority of human cancers. Despite this significance, the arsenal of high-quality chemical probes to interrogate these proteins remains limited. We used small molecule microarrays to identify compounds that bind Max in a mechanistically unbiased manner. We discovered the asymmetric polycyclic lactam, KI-MS2-008, which stabilizes the Max homodimer while reducing Myc protein and Myc-regulated transcript levels. KI-MS2-008 also decreases viable cancer cell growth in a Myc-dependent manner and suppresses tumor growth in vivo. This approach demonstrates the feasibility of modulating Max with small molecules and supports altering Max dimerization as an alternative approach to targeting Myc.National Cancer Institute (Grant R01-CA160860)National Cancer Institute (Grant P30-CA14051)National Cancer Institute (Grant U01-CA176152)National Cancer Institute (Grant CA170378PQ2)National Institutes of Health (Grant CA170378PQ2